CBD & Cannabis Statistics

At CannaHealth, our team works hard to find the latest CBD research, the most up to date medical cannabis study results, and present them to readers in an easy-to-understand way. In addition to publishing summaries of the newest, interesting, and most important research, we wanted to create a page where you can easily find the most relevant research related to your specific inquiry.

How to Use the CBD Statistics and Cannabis Page:

We’ve divided the results by ailment or category. Just use the Table of Contents below to find the ailment or area of interest you’re researching. For each, we’ve included the source, and the year the data was published.

For information that we’ve published about elsewhere on the site, you’ll find a link to easily access that content.

This page is being update all the time–consider subscribing to our weekly medical cannabis and CBD newsletter to stay on top of news and important research being done on the marijuana industry.


Cigarette smokers who used CBD smoked approximately 40% fewer cigarettes when using CBD. (Addictive Behaviors, 2013)

Owing to substantial methodological issues, previous epidemiological and clinical studies examining marijuana smoking on the risk of tobacco-sensitive lung diseases (e.g., lung cancer and chronic obstructive pulmonary disease [COPD]) have not produced consistent results. (Canadian Medical Association Journal, 2018)

In states where marijuana is available through medical channels, a modestly lower rate of opioid and high-risk opioid prescribing was observed. Medical marijuana legalization was associated with a lower odds of any opioid use: OR = 0.95 (0.94–0.96), chronic opioid use: OR = 0.93 (0.91–0.95), and high-risk opioid use: OR = 0.96 (0.94–0.98). (Journal of Internal Medicine, 2019)

States permitting medical marijuana dispensaries experience a relative decrease in opioid addictions and opioid overdose deaths (RAND BING Center for Health Economics, 2015)

Unlike other addictions, cannabis dependence of mild to moderate severity is not associated with dopamine release alterations in the brain. However, earlier or longer duration of use is related to lower dopamine release. These observations suggest a more harmful effect of using marijuana during adolescence. (Biological Psychiatry, 2012)

Thirty-two (32%) percent of people who try tobacco become dependent, whereas 15% who try alcohol and only 9% who try marijuana become dependent. (Berkeley Journal of Criminal Law, 2018)

There is emerging scientific evidence indicating that marijuana can serve as a pathway away from dependency of more dangerous substances, including prescription drugs, heroin, and alcohol. (Berkeley Journal of Criminal Law, 2018)

Aging Effects

64% of seniors rated their quality of life as “good” after using CBD, up from 31.1% prior to using CBD. (Remedy Review, 2018) 61.1% of seniors who tried CBD reported reduced pain. (Remedy Review, 2018)

45.6% of seniors who used CBD said it improved their sleep quality. (Remedy Review, 2018)

7.8% of seniors reported CBD improved their cognitive function. (Remedy Review, 2018)

5.6% of seniors who tried CBD reported decreased blood pressure. (Remedy Review, 2018)

Overall, 28.9% of CBD users over age 54 claimed it was “extremely effective” at treating symptoms.(Remedy Review, 2018)

Findings from a small study suggest that, when carefully matched on baseline variables and not differing in IQ or alcohol use, young, near-daily cannabis users do not differ from non-using control subjects in prospective memory performance. (Frontiers in Psychology, 2018)

Patients with dementia-related agitation and appetite loss who were treated with dronabinol – a cannabinoid – (average dosage =7.03 mg/d) experienced significant reductions in all aspects of agitation, including aberrant vocalization, motor agitation, aggressiveness, and treatment resistance (p <.0001), but no significant improvements in appetite. (Am J Geriatr Psychiatry, 2014).


Among people using benzodiazepines (commonly prescribed to reduce anxiety) who took CBD, 45.2% were able to stop using benzodiazepines. (Cannabis and Cannabinoid Research, 2019)

30% of people over age 54 reported CBD reduced their anxiety. (Remedy Review, 2018)

THC or CBD given in addition to other pharmacotherapies and psychotherapy improved specific symptoms of some disorders (e.g. in dementia, cannabis and opioid dependence, schizophrenia, general social anxiety, post-traumatic stress disorder, anorexia nervosa, attention-deficit/hyperactivity disorder, and Tourette`s disorder). (European Archives of Psychiatry and Clinical Neuroscience, 2019)

High-dose oral CBD (150–600 mg/d) may exert a therapeutic effect for social anxiety disorder, insomnia and epilepsy, but also that it may cause mental sedation (Cannahealth, 2019)

Existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive–compulsive disorder, and post-traumatic stress disorder when administered acutely; however, few studies have investigated chronic CBD dosing. (Neurotherapeutics, 2015)


61% of caregivers for children diagnosed with autism spectrum disorder (ASD) reported patients’ symptoms were “much improved” or “very much improved” after using CBD. (Journal of Autism and Developmental Disorders, 2018)

80% of parents whose ASD-positive children took CBD reported a decrease in problematic behavior that had been unaffected by conventional drugs, and 62% reported “significant improvement.” (Leafly, 2018)

50% of parents of children with ASD reported improved communication after taking CBD. (Leafly, 2018)

40% of ASD-positive children who used CBD showed significant decreases in anxiety. (Leafly, 2018)

Breastfeeding, Human Lactation and Pregnancy

Legalization of marijuana may give the false impression that marijuana is safe. Given ethical concerns, there are no randomized controlled trials on the effect of marijuana use by pregnant and lactating women, and the available longitudinal studies must be viewed with caution. However, highlighted in the available data are concerns regarding both short-term growth and long-term neurodevelopmental and behavioral consequences of prenatal exposure to marijuana. (The American Academy of Pediatrics, 2018)

Breastfeeding has numerous valuable health benefits for the mother and the infant, particularly the preterm infant. Limited data reveal that THC does transfer into human milk, and there is no evidence for the safety or harm of marijuana use during lactation. (The American Academy of Pediatrics, 2018)

Maternal exposure to marijuana during pregnancy could lead to dysregulation of the immune system of the developing fetus. This could potentially lead to immune deficiencies, infection, and even cancer later in life. (Cellular and Molecular Life Sciences, 2019)


Cannabinoids were shown to be of potential use for therapeutic approaches of glioblastoma. (Cell Adhesion & Migration, 2017)

CBD induced the death of breast cancer cells in a 2006 study. Researchers concluded that further investigation is needed to benefit from CBD’s potential to inhibit the growth of tumors. (Journal of Pharmacology and Experimental Therapeutics, 2006)

Cognitive Effects

In a study of adults with attention deficit hyperactivity disorder (ADHD), a positive effect was found on the measurements of hyperactivity and impulsivity, but not on the measurement of attention and cognitive performance. (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019)


High CBD (>9.5%) Low THC (<5.5%) cannabis was associated with the largest perceived changes in feelings of depression in a self-reported study. (Journal of Affective Disorders, 2018)


People aged 1 – 30 diagnosed with severe, treatment-resistant epilepsy reported a 36.5% median reduction in monthly motor seizures when using CBD. (The Lancet, 2015)

2% of epileptics using CBD reported a total cessation of seizures. (Scientific American, 2016)

Children age 2 – 18 diagnosed with Dravet syndrome (a drug resistant form of epilepsy involving convulsive seizures and high mortality) experienced a 22.8% reduction in seizures when using CBD. (New England Journal of Medicine, 2017)

Patients taking 20mg of CBD reported 42% decrease in seizures, while patients taking 10mg reported 37% reduction in seizures with fewer side effects. (New England Journal of Medicine, 2018)

Among parents of children taking CBD to treat severe epilepsy, 11% reported a complete cessation of seizures, 42% reported an 80% or more reduction in seizure frequency, and 32% reported a 25% – 60% reduction in frequency. (Epilepsy Behavior, 2013)

In a small study, CBD treatment for intractable epilepsy yielded a significant positive effect on seizure load. Most of the children (66/74, 89%) reported reduction in seizure frequency: 13 (18%) reported 75–100% reduction, 25 (34%) reported 50–75% reduction, 9 (12%) reported 25–50% reduction, and 19 (26%) reported <25% reduction. (Seizure – European Journal of Epilepsy, 2016)


Among adolescent patients (ages 13-23) with inflammatory bowel disease (IBD), 53% reported using marijuana most commonly for relief of physical pain. Users of marijuana were 10.7 times more likely to perceive low risk of harm with regular use of marijuana and perceived use of marijuana as beneficial for their condition. (Journal of Pediatrics, 2018).

Cannabinoids are well-established modulators of gut motility and visceral pain and have demonstrated anti-inflammatory properties. Clinical trials suggest that there may be a therapeutic role for cannabinoid therapy in the treatment of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), nausea and vomiting, and GI motility disorders. However, neither has been compared to standard therapy in IBD. (Current Gastroenterology Reports, 2019).


A recent meta-analysis of 11 studies concluded that legalization of medical marijuana up until 2014 did not lead to significant increases in adolescent marijuana use prevalence. (Society for the Study of Addiction, 2017)

Self-medication with marijuana was 21.22 percentage points higher among those people living in states with medical marijuana laws. (Drug and Alcohol Dependence, 2018)

Students with younger age at first use of marijuana had significantly higher odds of current marijuana use, a higher frequency of consumption, and were more likely to drive after use of marijuana. Effective enforcement of age restriction laws in combination with other prevention efforts may be beneficial in delaying the age of onset of marijuana until late adolescence and early adulthood. (Addictive Behaviors, 2019)

Colorado’s legalization of recreational cannabis sales and use resulted in a 0.7 deaths per month reduction in opioid-related deaths. This reduction represents a reversal of the upward trend in opioid-related deaths in Colorado, suggesting that legalization of cannabis is associated with short-term reductions in opioid-related deaths. (American Journal of Public Health, 2017)

The past fifty years of drug policy in the U.S. have demonstrated that we cannot criminalize people out of using substances. If we do, we are left with widespread consumption through an unregulated and uncontrolled market, making consumption and use more dangerous to the consumer. (Berkeley Journal of Criminal Law, 2018)

The Congressional Research Service projects that replacing criminalization with a system of taxation and regulation would yield a potential $6.8 billion in excise taxes. (Berkeley Journal of Criminal Law, 2018)

In a study aiming to understand why women typically demonstrate a more conservative stance on the issue of marijuana legalization than men, researchers found that the greater religiosity of women plays a role. The greater tendency of men to use marijuana as compared to women was found to be a major factor in this gender gap. (Social Science Quarterly, 2019)

Previous studies have demonstrated that states in the U.S. that have legalized marijuana have seen an increase in unintentional pediatric exposures in the years following legalization. Measures to mitigate or prevent toxicity, such as child-resistant packaging of marijuana products, have been taken by many states. (Clinical Pediatrics, 2019)

In 2017, for the first time, a majority of Republicans expressed support for legalizing marijuana; the current 51% demonstrated an increase of nine percentage points from 2016. (Gallup Poll: Social Series, 2017)

Americans continue to warm to legalizing marijuana, with 64% now saying its use should be made legal. This is the highest level of public support Gallup has found for the proposal in nearly a half-century of measurement. (Gallup Poll: Social Series, 2017)


100% of patients who experienced headaches and migraines reported a decrease in pain and discomfort when using CBD. (Care by Design, 2015)

Multiple Sclerosis (MS)

In patients with refractory multiple sclerosis (MS), after 12 weeks of treatment with nabiximols, an oral mucosal spray of a formulated extract of Cannabis that contains THC and CBD, patients experienced a statistically significant reduction in spasticity based on NRS score (P = .0002). (Eur J Neurology, 2011)

In a 2018 survey about cannabis treatment in migraine and headache, researchers found that chronic pain was the most common reason for cannabis use, consistent with most other registries. Hybrid strains were preferred in ID Migraine™, headache, and most pain groups, with “OG Shark”, a high THC (Δ9-tetrahydrocannabinol)/THCA (tetrahydrocannabinolic acid), low CBD (cannabidiol)/CBDA (cannabidiolic acid), strain. (The Journal of Headache and Pain, 2018)

Pain Management

97% of respondents reported using cannabis primarily for treating chronic pain and reported and average pain improvement on a 0–10 pain scale of 5.0, which translates to a 64% relative decrease in average pain. Half of all 100 respondents also noted relief from stress/anxiety, and nearly half (45%) reported relief from insomnia (Hawaii Journal of Medicine and Public Health, 2014)

About 81% of U.S. adults believe marijuana has at least 1 benefit, whereas 17% believe it has no benefit. The most common benefit cited was pain management (66%), followed by treatment of diseases, such as epilepsy and multiple sclerosis (48%), and relief from anxiety, stress, and depression (47%). (Annals of Internal Medicine, 2018)

Nabilone, dronabinol, and IM levonantradol (all cannabinoids) were found to be more effective in preventing vomiting and nausea among patients undergoing chemotherapy as compared with prochlorperazine, metoclopramide, chlorpromazine, thiethylperazine, haloperidol, domperidone, or alizapride (antiemetic medications). 38% to 90% of patients going through chemotherapy prefer medical marijuana over the traditional anti-vomiting and anti-nausea medications. (British Medical Journal, 2001)

Fifty-seven percent of patients with chronic pain given vaporized marijuana (average 8 to 12 puffs per visit) over 3 sessions reported pain reduction in a low-dose group and 61% of individuals reported pain reduction in a high-dose group. (Journal of Pain, 2013)

THC:CBD extract, a nonopioid analgesic containing CBD and THC extract, assists in relieving pain in patients with advanced cancer. Twice as many patients taking THC:CBD showed a reduction of more than 30% from baseline pain scores, demonstrating that THC:CBD extract is effective for relieving pain in patients with advanced cancer pain that is not fully relieved by strong opioids. (Journal of Pain and Symptom Management, 2010)

Pre-clinical and clinical studies have demonstrated that cannabis-based drugs have therapeutic potential in inflammatory diseases, including rheumatoid arthritis (RA) and multiple sclerosis. (Arthritis Research and Therapy, 2008)

Women with endometriosis, a condition where endometrial tissue is found outside the uterus causing severe pelvic pain, often turn to self-management strategies to deal with the symptoms. In a large sample of 480 women, cannabis, heat, hemp/CBD oil, and dietary changes were the most highly rated in terms of self-reported effectiveness in pain reduction. (BMC Complementary and Alternative Medicine, 2019)

Two recent case studies of men who had been in motor vehicle accidents and sustained spinal injuries demonstrate how CBD use may provide substantial pain relief – even more so than from the widely prescribed opioid and non-opioid analgesics. (Open Science Journal of Psychology, 2019)

Parkinson’s Diseases

Some preclinical studies and a small number of human trials indicate possible neuroprotective and therapeutic effects of cannabidiol (CBD) in patients with Parkinson’s Disease. (European Archives of Psychiatry and Clinical Neuroscience, 2019)

Post-Traumatic Stress Disorder (PTSD)

The use of nabilone (maximum dose: 3 mg/d), a synthetic cannabinoid, in military personnel with PTSD resulted in a significant (p =0.03) reduction in nightmares as measured by the CAPS recurrent distressing dream tool. (Psychoneuroendocrinology, 2015)

Data from 4 small studies suggested that cannabinoid use was associated with global improvements in PTSD symptoms or amelioration of specific PTSD symptoms such as insomnia and nightmares. (American Journal of Health-System Pharmacy, 2015)

PTSD patients saw a 75% reduction in PTSD symptoms when they were using cannabis compared to when they were not. (Journal of Psychoactive Drugs, 2014)

Currently, 24 states have approved medical cannabis specifically for the treatment of PTSD. These states include: Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida, Hawaii, Illinois, Maine, Michigan, Minnesota, Montana, Nevada, New Hampshire, New Mexico, New York, North Dakota, Ohio, Oregon, Pennsylvania, Rhode Island, Vermont, Washington, and West Virginia. (ECHO Connection, 2017)

MAPS has completed the first-ever clinical trial of smoked marijuana for symptoms of posttraumatic stress disorder (PTSD) in veterans of war. Results are due to be published in June of 2019. (Multidisciplinary Association for Psychedelic Studies)


Nighttime administration of THC reduced the frequency and intensity of nightmares in 72% of the 47 patients studied in a clinical trial. (CNS Neuroscience and Therapeutics, 2009)

Out of 72 adults presenting with primary concerns of anxiety or poor sleep, 79.2% experienced a decrease in anxiety scores within the first month of taking CBD in capsule form, which remained decreased during the study duration. Out of that sample, 66.7% of patients experienced improved sleep scores within the first month, but these scores fluctuated over time. (The Permanente Journal, 2019)

Recent use of cannabis at age 18 years was associated with poor sleep quality, suggesting a potential relationship between specific facets of cannabis use that are related to poor sleep in adolescents. (Psychology of Addictive Behaviors, 2019)


30% of people over age 54 reported lower stress levels a result of using CBD. (Remedy Review, 2018)

High CBD (>11%) High THC (>26.5%) produced the largest perceived changes in stress in a self-reported study. (Journal of Affective Disorders, 2018)


In patients with schizophrenia or schizophreniform disorder taking CBD for two to four weeks, there was a significant reduction of psychotic symptoms with no significant differences observed between CBD as treatment or an antipsychotic drug (amisulpride); however, CBD induced significantly less side effects (Brazilian Journal of Medical and Biological Research, 2006).


High CBD (>9.5%) Low THC (<5.5%) cannabis was associated with the largest perceived changes in feelings of depression in a self-reported study. (Journal of Affective Disorders, 2018)

High CBD (>11%) High THC (>26.5%) produced the largest perceived changes in stress in a self-reported study. (Journal of Affective Disorders, 2018)

In one small study, a THC+CBD strain was associated with lower levels of cannabis craving, subjective intoxication, and circulating cytokines among participants immediately after use. (Cannabis and Cannabinoid Research, 2018)